

TITLE PAGE

Category of manuscript: Original Article – Laboratory Science.

Title of the Paper: How urgent do intravitreal anti-VEGF injections need to be to justify the risk of transmitting COVID-19? Proof-of-concept calculations to determine the Health Adjusted Life-Year (HALY) trade-off.

Full names and highest degree/qualifications of authors:

Matt James Boyd¹ MBChB PhD

Daniel Andrew Richard Scott² MBChB

David Michael Squirrell³ FRCOphth

Graham Ashley Wilson^{2,4} FRANZCO MOphth

Addresses of institutions at which the work was carried out

¹ Adapt Research Ltd, Reefton, New Zealand

² Department of Ophthalmology, Gisborne Hospital, Hauora Tairāwhiti, Gisborne, New Zealand

³ Department of Ophthalmology, Greenlane Clinical Centre, Auckland District Health Board, Auckland, New Zealand

⁴ Matai Lab, Gisborne, New Zealand

Corresponding author

Dr Matt Boyd

14 Broadway, Reefton 7830, New Zealand

+64223512350, mattjamesboyd@gmail.com

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

Short running title:

Benefit of anti-VEGF vs risk of COVID-19

Declaration of competing/conflicts of interest:

The authors declare no conflicts of interest

Declaration of funding sources:

Self-funded

ABSTRACT and KEYWORDS

Background: Clinical ophthalmological guidelines encourage the assessment of potential benefits and harms when deciding whether to perform elective ophthalmology procedures during the COVID-19 pandemic, in order to minimize the risk of disease transmission.

Method: We performed probability calculations to estimate COVID-19 infection status and likelihood of disease transmission among neovascular age-related macular degeneration patients and health care workers during anti-VEGF procedures, at various community prevalence levels of COVID-19. We then applied the expected burden of COVID-19 illness and death expressed through health-adjusted life-years (HALYs) lost. We compared these results to the expected disease burden of severe visual impairment if sight protecting anti-VEGF injections were not performed.

Results: Our calculations suggest a wide range of contexts where the benefits of treatment to prevent progression to severe visual impairment or blindness are greater than the expected harms to the patient and immediate health care team due to COVID-19. For example, the benefits of treatment outweigh harms when the chance of progression to severe visual impairment is $>0.37\%$ for all scenarios where COVID-19 prevalence was 2000 per million, even when the effective attack rate in the clinical setting is very high (5–43%).

Conclusion: Unless COVID-19 prevalence is very high, the reduced disease burden from avoiding visual impairment outweighs the expected HALYs lost from COVID-19 transmission. This finding is driven by the fact that HALYs lost when someone suffers severe visual

impairment for 5 years are equivalent to nearly 400 moderate cases of infectious disease lasting 2 weeks each.

Keywords: Age-Related Macular Degeneration, anti-VEGF, COVID-19, Health-Adjusted Life-Years, Mathematical Model.

MANUSCRIPT

Introduction

The coronavirus causing COVID-19 disease began circulating in Wuhan, China, in November 2019, quickly becoming a global pandemic. Italy was an early epicenter of the pandemic and Italy's national medical federation reported that 10% of responding health-care workers had been infected with 125 attributed-physician deaths recorded from 11 March to 17 April 2020.¹ In New York City when that city was the epicenter of the pandemic (March–April 2020), ophthalmology residents had the fifth highest proportion of infections among specialties, with 5% of residents confirmed to have acquired COVID-19. It cannot be ascertained whether this was in the line of work or not. For comparison 2.4% of GPs and 1.1% of diagnostic radiologists had confirmed infection.² The risk of transmission from patient to health care team, and among members of health care teams, clearly must be mitigated.

Advice in recent ophthalmologic guidelines suggests that a clinical evaluation of the benefits and harms of performing eye procedures during the COVID-19 pandemic should determine whether to proceed or defer interventions.³ This means that clinicians should be using clinical judgment to weigh the probability of serious progression of eye disease against the probability that COVID-19 might spread among patients and health care staff. Patients with non-urgent clinical conditions (such as stable glaucoma and amblyopia) and non-urgent surgical conditions (such as cataract or epiretinal membrane) can be scheduled later.³ For those requiring urgent clinical assessment or procedures, stringent isolation and protection measures should be integrated into the workflow. One major consideration is the availability of personal protective equipment (PPE) for health care workers.⁴ However, it is useful to have an approximate

quantitative estimate of benefits and harms of proceeding with an intervention to guide clinical decision-making.

In the present analysis we focus on intravitreal injections in the New Zealand context. These have become the most common procedure in both ophthalmology and medicine.⁵ Injection of anti-vascular endothelial growth factor (anti-VEGF) for treatment of neovascular age-related macular degeneration (nAMD) is the most common indication.⁶ Since their introduction to New Zealand there has been a significant reduction to the nAMD-associated blindness.⁷ The expected cost per quality adjusted life-year for sight improvement/maintenance from this treatment is estimated at NZ\$2,900. In the New Zealand health setting, most nAMD treatments are delivered by the public health service, with less than 10% of volume performed in private.⁷

Triage guidelines released by The Royal Australian and New Zealand College of Ophthalmologists (RANZCO) recommend continuing clinic appointments during the COVID-19 pandemic for nAMD patients with a high urgency.⁸ The American Macular Degeneration Foundation shares a similar position, stating that 'anti-VEGF injections are essential for those who require them'.⁹ This is because the risks of stopping or delaying treatments for nAMD are significant. A delay in providing treatment is known to increase the risk of disease reactivation and visual loss.¹⁰ As a lifelong chronic disease, even with good disease control, continued anti-VEGF injections are recommended to reduce the risk of reactivation.¹¹ We know from an observational study of 434 eyes where treatment was suspended, that 41% experienced disease reactivation within the first year.¹² In a large cohort study from the United Kingdom, just 6.9% of nAMD patients became legally blind following 2 years of anti-VEGF, compared to a predicted figure of 15.7% for untreated patients.¹³

COVID-19 imposes a high burden of morbidity and mortality upon communities through illness and death. However, severe vision impairment and blindness due to untreated eye conditions such as AMD also imposes quality of life losses. The clinical judgment equation must determine whether to treat or defer after balancing these competing impacts on health.

In this paper, we compare the burden of disease due to severe vision impairment against the possible burden due to COVID-19 transmission among nAMD patients and the healthcare team at various community levels of infection prevalence. We aimed to estimate the probability of progression to severe vision impairment in the New Zealand setting that might justify nAMD treatment rather than deferral for individual cases during the COVID-19 pandemic.

Method

We developed a simple model of COVID-19 transmission and illness impacts. This model accounts for the true background prevalence of COVID-19 disease in the community, and therefore the probability that health care workers or the patient (drawn randomly from the population) are currently infected, the probability of transmission among these individuals at the time of treatment based on attack rate data, the health impact in terms of vision impairment, COVID-19 infection, and life years lost due to death from COVID-19. The parameters used in the model are displayed in Table 1.

The health impact of COVID-19 and visual impairment was compared using calculations of health-adjusted life years (HALY), which measure the combined effects of mortality and morbidity. One HALY is equivalent to one year of life lived in good health. For individual diseases annualized disability weights (DW) have been calculated which when applied for the

duration of illness have the net effect of reducing the health of a life-year by a fractional component. The Global Burden of Disease (GBD) Study used surveys to obtain data on paired comparisons of different health states and calculated and published DWs for a range of conditions.¹⁴ For example, the GBD DW for a 'moderate infectious disease' was 0.051, which can be applied for the duration of disease to quantify a one-time health impact. For a chronic condition like severe distance vision impairment the GBD DW of 0.184 would be applied per annum (for remaining expected lifetime if permanent). In our model life years were health adjusted, meaning that any loss of life years was already adjusted for morbidity such as the expected level of pre-existing illness by age group.

Data from contact tracing in China suggest a risk of infection by COVID-19 to close contacts of 1–5%.¹⁵ Whereas data from a study of transmission in a South Korean call center suggest an attack rate of up to 43% for those who spend day after day in close proximity without protective equipment.¹⁶ We modelled both these scenarios.


For simplicity we assumed a healthcare team of 3 members for a standard ophthalmologic procedure such as anti-VEGF injection for nAMD (injector, nurse, and additional assistant/clinic staff). This means the patient experiences three possible exposures to COVID-19 and each healthcare team member is exposed to two other staff and the patient. When calculating the impact of vision loss we assumed the patient already had moderate distance vision loss (better eye), with visual impairment: <6/18 to 6/60, (DW 0.031) and was at risk of progressing to severe distance vision loss, <6/60 to 3/60, or blindness, <3/60, (DW 0.184 and 0.187 respectively) which were treated as equivalently bad outcomes for simplicity.

Given that severity of illness and death from COVID-19 vary by age, we assumed an average healthcare worker age in New Zealand of approximately 50 years.¹⁷ We analysed a number of scenarios including where a patient of mean age for AMD treatment in New Zealand receives monthly anti-VEGFs across six months, also a scenario where a patient of younger age (65-69 years) receives a single treatment. We also evaluated scenarios assuming the transmission probability reported for 'close contacts' was reduced by 95% due to the impact of full PPE used by all staff (gloves, goggles, face shields, water resistant gowns, and respiratory protective equipment). Finally, the expected gain/loss in terms of HALYs for a single average patient was scaled up by the number of patients expected to receive anti-VEGF injections in a 6-month period to estimate total potential HALY impact in the New Zealand context.

Our coarse-grained model assumed a new health care team at each treatment occasion as a simplifying assumption in order to avoid the complication of tracking those who had been infected and recovered. Population prevalence of COVID-19 was assumed to be static across time for repeat procedures.

Figure 1 illustrates how the model works by calculating the probability that transmission of COVID-19 occurs during treatment and then attributing health impacts to these cases according to age and statistical severity of illness. It also attributes health impacts for progression of visual impairment, and these values are then used to determine the probability of progression which equals the health impact of COVID-19 transmission.

Figure 1: Model to compare likely HALY loss due to COVID-19 transmission among patient and immediate healthcare team against HALY loss due to progression of visual impairment without treatment



DW: disability weight, HALY: health-adjusted life year, PPE: personal protective equipment

Table 1: Parameters used in the proof-of-concept model to estimate expected health-adjusted life-year impact of proceeding with anti-VEGF injections in the context of COVID-19 pandemic.

Parameter	Value	Source
Mean 5-year age group of those undergoing anti-VEGF for AMD	75-79 years 65-69 years	Ernst & Young (2017) report the mean age of those undergoing anti-VEGF is 79 years. ⁷ 65-69 year age group was included for the 'younger patient, single treatment' scenario
Average age of health care workers	50	Approximate (in New Zealand average nurse age is reported to be 46, and 40% of doctors are older than 50). ¹⁷
Health adjusted life expectancy (HALE) in New Zealand by age group	Varies by age, eg 9.1 years for those aged 70-79	Kvizhinadze et al (2015). ¹⁸
Excess disability weight for severe visual impairment over moderate visual impairment (annualised)	0.153	Difference between 0.031 and 0.184, Salomon (2015). ¹⁴
Probability of COVID-19 transmission from 'close contact'	5%-43%	WHO-China Joint COVID-19 Report reports that 1-5% of close contacts became infected. ¹⁵ The value of 5% is used in our model. Park et al. (2020) detail an attack rate of 43% on one floor of a call-centre in South Korea. ¹⁶

Probability of COVID-19 transmission with 'N95 mask or similar respirator'.	4%	Chu et al. (2020). ¹⁹
Disease burden from infectious disease (DW, annualised)	0.006 mild 0.051 moderate 0.133 severe	Salomon (2015), applied to proportion of the year that the individual is ill. ¹⁴
Disease burden for visual impairment or blindness (DW annualised)	0.031 moderate 0.184 severe 0.187 blindness	Salomon (2015). ¹⁴ We used 0.153 applied annually (the difference between moderate and severe) in our model. This errs on the side of minimising the DW for loss of vision, thereby strengthening the case for undertaking the procedure if it turns out that health loss for visual decline outweighs health loss from COVID-19
Duration of COVID-19 illness (to apply annualised DW)	22.6 days (hospitalised cases)	Verity et al. (2020). ²⁰ (we therefore assumed 14 days duration for moderate cases, and 7 days for mild cases).
Probability of severe COVID-19 illness	Varies by age (eg 70-79 years = 24.3%)	Ferguson et al. (2020). ²¹
Probability of death from COVID-19	Varies by age (eg 70-79 years = 5.1%)	Ferguson et al. (2020). ²¹
Number of procedures required in 6 months	Scenario analyses: 6 (eg monthly anti-VEGF injections) 1 (eg single procedure)	Authors' estimates.
Effective number of health care staff per 'procedure'	3	Authors' estimate: includes ophthalmologist, nurse, clinic assistant
Parameters varied in the model		
Probability of progression from moderate to severe visual impairment without treatment	Varied in model	Varied to establish 'break-even' point where expected HALYs gained = 0.
Population prevalence of COVID-19	Varied in model	Varied from 200 per million to 200,000 per million. Chosen because at the time of writing COVID-19 prevalence in New Zealand was approximately 200 cases per million

AMD: age-related macular degeneration, DW: disability weight, HALY: health-adjusted life-year, VEGF: vascular endothelial growth factor

Results

Key results are summarized in Table 2. The results are presented with respect to three dimensions, (1) the presumed relevant attack rate of COVID-19 in a clinical setting (scenarios of 5% and 43%), (2) the availability of full appropriate PPE (that reduces transmission by 95% versus not at all), and (3) by the community prevalence of active COVID-19. The results are expressed as the probability of progression to severe vision impairment or blindness at which the modelled health impact of visual impairment progression (due to not doing the procedure) exceeds the expected health impact from transmission of COVID-19 among the patient and immediate healthcare team.

Table 2: Results expressed as the probability of progression to severe visual impairment, which would justify treatment given the prevalence of COVID-19 and availability or not of full personal protective equipment (PPE).

	Six monthly treatments, involving three 50-year-old health care workers and a patient aged 75–79 years		Single treatment, involving three 50-year-old health care workers and a younger patient aged 65–69 years	
Community prevalence COVID-19	Attack rate 5%	Attack rate 43%	Attack rate 5%	Attack rate 43%
PPE is available and 95% effective (eg gown, gloves, N95 mask, face shield, cap)				
0.0002 (200 per million)	0.004%	0.04%	0.0001%	0.016%
0.002	0.04%	0.37%	0.001%	0.157%
0.02	0.43%	3.7%	0.01%	1.57%
0.2	4.25%	37%	0.1%	15.7%
PPE is not available (eg just gloves, surgical mask)				
0.0002	0.09%	0.73%	0.002%	0.31%
0.002	0.85%	7.3%	0.022%	3.14%
0.02	8.5%	73%	0.22%	31.4%
0.2	85%	Not justified	2.22%	Not justified

‘Not justified’: treatment likely to cause more harm from COVID-19 than the benefit of preserving vision; PPE: personal protective equipment.

Percentages indicate the probability of progression to severe visual impairment without treatment; for example with PPE available and community prevalence of 0.0002, then a one-time treatment is justified for a very low (>0.0001%) probability of progression, however, with no PPE and prevalence of 0.2 then a monthly treatments across six months are only justified if the patient will almost certainly (85%) progress to severe visual impairment without treatment.

For example, for a one-time procedure under the assumptions that the relevant COVID-19 attack rate is 5%, full PPE is available, and the community prevalence of active COVID-19 is only 0.0002 (ie 200 cases per million population), then the procedure might be considered for a 65–69 year old if the likelihood of progression to severe visual impairment (or blindness) was as low as 0.0001% or more. For the same scenario, if the relevant attack rate is 43% and the prevalence is 0.2 (20% of the population has active COVID-19), then the likelihood of progression to permanent severe visual impairment without treatment would need to be greater than 15.7%.

Repeated treatments (eg monthly injections for six months) expose the patient and healthcare staff to a much higher chance of spreading the infection and results reflect that fact. For example, if the attack rate is 5% and 20,000 per million are infected, then the chance of severe visual impairment without treatment must exceed 8.5% or the harm to health from COVID-19 transmission exceeds that of permanent visual impairment.

The HALYs driving these calculations were calculated. Two examples illustrate the findings. First, we analysed the scenario where PPE is not available, the probability of progression to severe visual impairment, or worse, is 5% without treatment, the attack rate is 5%, and the patient is in the 75–79 age group needing monthly treatments. Results for this scenario indicate the expected HALY benefit (accounting for COVID-19 impact and vision loss avoided) is +0.07 at a COVID-19 prevalence of 200 per million, but becomes an expected loss of 1.11 HALYs if 200,000 per million of the population are infected.

In a second scenario, for a patient aged 65–69 years, needing a single procedure there is a gain of 0.12 HALYs when the population prevalence of COVID-19 is only 200 per million. This is

made up of an expected gain of 0.12 HALY due to prevention of vision loss, and a negligible HALY loss due to the spread of infection. This changes to an expected HALY loss of 0.04 (due to harm from COVID-19 infection outweighing benefits for vision) if the probability of severe visual impairment by deferring treatment for 6 months is only 0.5% (rather than 5%) and the prevalence of COVID-19 is very much higher at 200,000 per million.

Applying the assumption that correct use of good quality PPE reduces the likelihood of transmission by 95%, we found HALY benefits in all scenarios where the probability of progression to severe visual impairment without treatment was assumed to be 5%. The HALY benefit is +0.01 even at 200,000 per million COVID-19 prevalence (in this case the threshold for a zero net HALY impact is 4.25% chance of progression, as per Table 2).

Finally, the expected HALY gains per procedure can be scaled up by applying case volumes. For example, in New Zealand, there are more than 75,000 anti-VEGF injections performed annually (unpublished data, available from authors). Assuming monthly injections, this means there are potentially 6000 patients getting treatment in a six-month period. If even 1% of nAMD patients are at risk of progressing to severe visual impairment, then there are more than 87 net HALYs to be gained by continuing injections while the prevalence of COVID-19 in New Zealand is below 200 per million.

Discussion

Our results indicate that for the most plausible community prevalence rates of COVID-19 and with availability of appropriate PPE, then ophthalmic procedures should be considered more beneficial than the likely harm from COVID-19 in many cases provided there is a non-negligible probability of progression to severe visual impairment without treatment. The reason for this result is easily illustrated by considering that the HALYs lost when someone suffers severe visual impairment for 5 years are equivalent to nearly 400 moderate cases of infectious disease lasting 2 weeks each.¹⁴ The difference in disease burden expressed as annualised disability weight (DW) for a shift from moderate distance vision impairment to severe distance vision impairment is 0.153, whereas the DW for a 'moderate infectious disease' is 0.051, which only applies for the duration of illness.¹⁴ COVID-19 can be a severe and deadly disease, nevertheless the burden of vision loss is significant and ongoing.

Notably, for all scenarios where COVID-19 prevalence is less than 2000 per million population and proper PPE is available, a 1% likelihood of progression to severe visual impairment or blindness without treatment will tend to justify treatment. However, if there was a rapid escalation of COVID-19 cases, the 'break even' point at which HALYs lost rather than gained from providing care will change. We find that if one in five members of the population carries active virus, and PPE is in short supply, then the expected harms from COVID-19 outweigh the benefits of anti-VEGF treatments even when the chance of severe visual impairment without treatment is very high.

A number of other factors need to be considered beyond our simple model. Firstly, we encourage the development of more sophisticated and accurate epidemiological models of the likelihood of COVID-19 transmission in healthcare settings, given a range of contextual factors.

We also encourage the development of estimates of the probability of severe visual impairment if eye conditions are untreated. This would allow models to output the expected HALYs gained and lost, rather than the probability of progression (requiring clinical judgement) at which the intervention 'breaks even' in terms of HALYs.

Secondly, given the high number of undetected COVID-19 cases in the community then ideally the true prevalence is established by random testing. In Austria, as at early April 2020, such studies revealed an active case prevalence of 0.33%.²² Early random community testing in New Zealand indicated zero community prevalence as at 20 April, 2020.²³

Thirdly, our evaluation considers individual cases and assumes that the healthcare team is different each time for repeated procedures. This means that cumulative risk to individual health care workers who may perform many procedures, is not evaluated. The risk to individuals who are likely to be repeatedly exposed ought to be considered when weighing benefits and harms. That said, even without effective PPE, and with a COVID-19 population prevalence of 200,000 per million, the expected HALY loss to health care workers due to COVID-19 infection appears to be approximately 0.0001 per person per procedure. The reason is that for the vast majority of people COVID-19 is a mild infectious illness for a week or two.²⁴ In the model this is weighed against severe visual impairment for the remainder of the patient's life.

Finally, local COVID-19 mitigation strategies should be considered. In contexts where mitigation of disease impact or suppression of the number of cases is the goal, then the arguments above will apply. However, if the aim is elimination of COVID-19 then extra consideration might be given to avoiding all personal contact, including ophthalmologic

procedures. However, if patients recover at home in quarantine, and it is possible to keep health care teams in small ‘bubbles’, then the risks might be managed.

A further consideration when weighing up whether to proceed with interventions or not is future demand. For example, without continuing elective anti-VEGF injections where feasible, there is a risk of post-pandemic surge in demand. Health authorities need to plan ahead in order to avoid a mismanaged flow, and minimize staff burnout.²⁵ We are mindful that the reasoning described in this paper will apply to a number of other procedures where untreated conditions are likely to result in a high burden of disease. The benefits and harms of performing procedures for these conditions should also be quantified.

The risk of COVID-19 spread can be further mitigated by appropriate health facility processes, including staff rotation, physical distancing, handwashing and disinfection, alert signs, no touch payments and many other measures.³ A study of 30 confirmed and suspected COVID-19 patients undergoing caesarean section reported no infection of healthcare workers.²⁶ This shows that transmission can be kept low under optimal conditions. Effective PPE makes a dramatic difference to the calculus. Furthermore, patients and staff could be tested for COVID-19 and could remain in self-quarantine following contact.

During this unique period of a global pandemic, the equation for continuing to provide care becomes more complicated. For ophthalmologists, there is a mindset change from patient-centered (preventing vision loss) to a community-centered (preventing spread of infectious disease and death) perspective. The personal health risks that the ophthalmology team and our patients take must be carefully considered. The average age for nAMD patients increases their risk for severe illness and death given age is one of the most important risk factors.²⁷

Likewise, ophthalmologists are currently overrepresented in physician deaths attributed to COVID-19 (4% of all physicians) possibly reflecting their close contact with patients. Dr. Li Wenliang, the ophthalmologist and whistleblower who informed the world of COVID-19, died of the disease.²⁸ Our calculations show that with appropriate PPE (sufficient to reduce transmission probability by 95%), the transmission risks are almost zero, even with high COVID-19 prevalence, however the limiting factor will be the availability of this equipment.

Limitations

This analysis is only a proof-of-concept using a simple coarse-grained model. We have not accounted for a number of variables including the possible spread of any COVID-19 acquired during procedures to others beyond the patient and healthcare team. For repeat procedures across a six-month pandemic period we have assumed a constant community prevalence of COVID-19, however this would peak and decline. More sophisticated epidemiological models should be developed to account for these variables. Also, our model applies the DW for progression from 'moderate visual impairment' to 'severe visual impairment/blindness' as an immediate transition, which does not account for slow deterioration and will likely overestimate HALY losses. We have also assumed just three healthcare staff exposed to each other and each patient, however, real clinical interactions may involve more close contacts than this. We have assumed that high-quality PPE reduces the chance of infection by 95% (ie one in twenty close contacts using PPE are exposed to the risk of infection). Although, this could still be conservative, as we note above, some reports suggest very low or no COVID-19 transmission in surgical settings (zero infections during 30 caesarean deliveries in one study). Our analysis also, does not consider whether health resources might better be spent treating COVID-19 patients. Our analysis was performed in the context of New Zealand's population demographic, including age at treatment and health adjusted life-expectancy and findings may

not generalise to other settings. Finally, the COVID-19 pandemic is evolving and so the parameters used in the model are dynamic and subject to change over time as more information and further research becomes available.

Conclusion

Recent clinical guidelines emphasise the need for clinicians to consider the benefits and harms of performing clinical procedures during the COVID-19 pandemic. We estimated the expected HALYs lost due to COVID-19 transmission in the clinical setting, and the expected HALY gains from preventing progression of eye disease from moderate impairment to severe impairment.

Our simple calculations suggest that with appropriate PPE, the threshold for carrying out interventions is likely to be low, with a 1% chance of severe visual impairment or blindness without treatment justifying interventions in scenarios we analysed, except where there is very high population prevalence of COVID-19 disease.

REFERENCES

1. Fedarazione Nazionale degli Ordini del Medici Chirurghi e degli Odontoiatri. *Elenco dei Medici caduti nel corso dell'epidemia di Covid-19*. Rome: Federazione Nazionale degli Ordini dei Medici Chirurghi e degli Odontoiatri; 2020. Accessed April 2020. Available from: <https://portale.fnomceo.it/elenco-dei-medici-caduti-nel-corso-dellepidemia-di-covid-19/>.
2. Breazzano M, Shen J, Abdelhakim A, Glass L, Horowitz J, Xie S, et al. Resident physician exposure to novel coronavirus (2019-nCoV, SARS-CoV-2) within New York City during exponential phase of COVID-19 pandemic: Report of the New York City Residency Program Directors COVID-19 Research Group. *MedRxiv*. 2020. doi: <https://doi.org/10.1101/2020.04.23.20074310>.
3. Gharebaghi R, Desuatels J, Moshirfar M, Parvizi M, Daryabari S, Heidary F. COVID-19: Preliminary Clinical Guidelines for Ophthalmology Practices. *Med Hypothesis Discov Innov Ophthalmol*. 2020;**9**:149–58. doi: 10.1136/bmjophth-2020-000487.
4. The Lancet. COVID-19: protecting health-care workers. *Lancet*. 2020;**395**:922. doi: 10.1016/S0140-6736(20)30644-9.
5. Lau PE, Jenkins KS, Layton CJ. Current Evidence for the Prevention of Endophthalmitis in Anti-VEGF Intravitreal Injections. *J Ophthalmol*. 2018;**2018**:8567912. doi: 10.1155/2018/8567912.
6. Parikh R, Ross R, Sangaralingham L, Adelman R, Shah N, Barkmeier A. Trends of Anti-Vascular Endothelial Growth Factor Use in Ophthalmology Among Privately Insured and Medicare Advantage Patients. *Ophthalmol*. 2016;**124**:352-8. doi: 10.1016/j.ophtha.2016.10.036.

7. Ernst & Young. *Age-related Macular Degeneration Model of care assessment and recommendations*. Ernst & Young; 2017.
8. Royal Australian and New Zealand College of Ophthalmologists (RANZCO). *RANZCO New Zealand Branch Triage Guidelines – COVID-19 Level 4*. Sydney: Royal Australian and New Zealand College of Ophthalmologists; 2020. Accessed April 2020. Available from: <https://ranzco.edu/wp-content/uploads/2020/04/RANZCO-triage-NZ-modification-level-4.pdf>.
9. Seddon J, Khurana R. *Coronavirus and Your Macular Degeneration Care*. Northampton: American Macular Degeneration Foundation; 2020. Accessed April 2020. Available from: <https://www.macular.org/2020/03/19/coronavirus-and-your-macular-degeneration-care>.
10. Ozturk M, Harris ML, Nguyen V, Barthelmes D, Gillies MC, Mehta H. Real-world visual outcomes in patients with neovascular age-related macular degeneration receiving aflibercept at fixed intervals as per UK licence. *Clin Exp Ophthalmol*. 2018;**46**:407-11. doi: 10.1111/ceo.13085.
11. Gale RP, Mahmood S, Devonport H, Patel PJ, Ross AH, Walters G, et al. Action on neovascular age-related macular degeneration (nAMD): recommendations for management and service provision in the UK hospital eye service. *Eye (Lond)*. 2019;**33**:1-21. doi: 10.1038/s41433-018-0300-3.
12. Nguyen V, Vaze A, Fraser-Bell S, Arnold J, Essex RW, Barthelmes D, et al. Outcomes of Suspending VEGF Inhibitors for Neovascular Age-Related Macular Degeneration When Lesions Have Been Inactive for 3 Months. *Ophthalmol Retina*. 2019;**3**:623-8. doi: 10.1016/j.oret.2019.05.013.

13. Buckle M, Lee A, Mohamed Q, Fletcher E, Sallam A, Healy R, et al. Prevalence and incidence of blindness and other degrees of sight impairment in patients treated for neovascular age-related macular degeneration in a well-defined region of the United Kingdom. *Eye (Lond)*. 2015;**29**:403-8. doi: 10.1038/eye.2014.296.
14. Salomon JA, Haagsma JA, Davis A, de Noordhout CM, Polinder S, Havelaar AH, et al. Disability weights for the Global Burden of Disease 2013 study. *Lancet Glob Health*. 2015;**3**:e712-23. doi: 10.1016/s2214-109x(15)00069-8.
15. WHO-China Joint Mission. *Report of the WHO-China Joint Mission on Coronavirus Disease 2019 (COVID-19)*. World Health Organization; 2020.
16. Park S, Kim Y, Yi S, Lee S, Na B, Kim C. Coronavirus disease outbreak in call center, South Korea. *Emerg Infect Dis*. 2020;**26**. doi: 10.3201/eid2608.
17. Immigration New Zealand. *Building and keeping a health workforce*. Wellington: Immigration New Zealand; 2015. Accessed April 2020. Available from: <https://www.immigration.govt.nz/about-us/media-centre/newsletters/settlement-actionz/actionz3/building-and-keeping-a-health-workforce>.
18. Kvizhinadze G, Wilson N, Nair N, McLeod M, Blakley T. How much can society spend on life-saving interventions at different ages while remaining cost effective? Estimates using New Zealand health system costs, morbidity, and mortality data. *Population Health Metrics*. 2015;**13**. doi: 10.1186/s12963-015-0052-2.
19. Chu D, Akl E, Duda S, Solo K, Yaacoub S, Schünemann H. Physical distancing, face masks, and eye protection to prevent person-to-person transmission of SARS-

CoV-2 and COVID-19: a systematic review and meta-analysis. *Lancet*. 2020. doi:

[https://doi.org/10.1016/S0140-6736\(20\)31142-9](https://doi.org/10.1016/S0140-6736(20)31142-9).

20. Verity R, Okell L, Doriagatti I, Winskill P, Whittaker C, Imai N. Estimates of the severity of COVID-19 disease. *MedRxiv*. 2020. doi:

<https://doi.org/10.1101/2020.03.09.20033357>.

21. Ferguson N, Laydon D, Nedjati-Gilani G, Imai N, Ainslie K, Baguelin M, et al. *Impact assessment of non-pharmaceutical interventions (NPIs) to reduce COVID-19 mortality and healthcare demand*. London: Imperial College; 2020. Report No.: 9.

doi: <https://doi.org/10.25561/77482>.

22. Ogris G, Hofinger C. *COVID-19 Prevalence: Media information, April 10*. Sora Institut; 2020.

23. New Zealand Government. *Transcript of COVID-19 media conference – 20 April*. Wellington: New Zealand Government; 2020. Accessed April 2020. Available from: <https://covid19.govt.nz/latest-updates/covid-19-media-conference-20-april/transcript-of-covid-19-media-conference-20-april/>.

24. Sharma R, Agarwal M, Gupta M, Somendra S, Saxena S. Clinical Characteristics and Differential Clinical Diagnosis of Novel Coronavirus Disease 2019 (COVID-19). *Coronavirus Disease 2019*. 2020:55-70. doi: 10.1007/978-981-15-4814-7_6.

25. Zhang H, Bo L, Lin Y, Li F, Sun S. Response of Chinese Anesthesiologists to the COVID-19 Outbreak. *Anesthesiology*. 2020. doi:

10.1097/ALN.0000000000003300.

26. Yue L, Han L, Li Q, Zhong M, Wang J, Wan Z, et al. Anaesthesia and infection control in cesarean section of pregnant women with coronavirus disease 2019 (COVID-19). *MedRxiv*. 2020. doi: <https://doi.org/10.1101/2020.03.23.20040394>.
27. Jordan R, Adab P, Cheng K. Covid-19: risk factors for severe disease and death. *BMJ*. 2020;**368**. doi: [10.1136/bmj.m1198](https://doi.org/10.1136/bmj.m1198).
28. Ing E, Xu A, Salimi A, Tourun N. Physician Deaths from Corona Virus Disease (COVID-19). *MedRxiv*. 2020. doi: <https://doi.org/10.1101/2020.04.05.20054494>.